Suven Life Sciences
Suven Life Sciences provides drug discovery and development support services to global pharmaceutical and biotech companies.
Suven Life Sciences provides drug discovery and development support services to global pharmaceutical and biotech companies.
suven.comCrawled Oct 25, 2026
Suven provides high quality in vitro ADME and in vivo pharmacokinetics for preclinical, clinical candidate selection and drug product development.
Suven provides complete array of analytical services, to support the drug development, process research and product release procedures.
Suven Life Sciences provides drug discovery and development services, including chemistry, assay screening, and pharmacology research, to global pharma and biotech companies.
Suven offers assay development and screening for target class GPCRs, ion channels, and transporters.
Professional environment, high standards and ample growth opportunities make Suven an ideal place to work. An equal opportunity employer, Suven provides a plethora of different roles helping one to gain valuable exposure. The nature of engagement becomes more intense as one progresses.
Suven Life Sciences is managed by a team of thoroughbred professionals who have been guiding the company prospects in the domestic and international arenas with their seasoned skills, knowledge and expertise lending value to and contributing to the growth of the Company.
Incorporated as a Privated Limited Company in 1989.
SUVEN’s CSR policy aims to build economic, social, and environmental capital in the communities where it operates.
6th Floor, SDE Serene Chambers, Avenue - 7, Road No. 5, Banjara Hills, Hyderabad-500 034, Telangana, INDIA.
6th Floor, SDE Serene Chambers, Road No 5, Avenue 7, Banjara Hills, Hyderabad, Telangana - 500034
The code outlines ethical standards for directors and senior management at Suven Life Sciences and its subsidiaries, exceeding legal requirements.
Suven Life Sciences finishes enrolling **424 patients** in its global Phase-3 trial of **masupirdine** for treating **Alzheimer’s agitation**, surpassing the original target of 375 participants. The **double-blind, placebo-controlled study** spans sites in the **USA and Europe**, with final patient visits due by **December 2026**. Topline results are expected by **May 2027**.
Sep 2026scanx.tradeNews article
Suven is advancing its late-stage pipeline of drugs targeting central nervous system disorders. The company specializes exclusively in neuroscience innovations, positioning itself as a leader in this specialized therapeutic area. Clinical trials for its key candidates are nearing completion, marking a critical phase in development.
Jul 2026mintNews article
Suven Life Sciences presents three posters at the APSS meeting in the US, detailing Phase 2 results and Phase 3 plans for its narcolepsy treatment, SLEEP-2026. The clinical-stage biotech highlights progress in its drug development pipeline targeting sleep disorders. The presentations focus on clinical trial outcomes and next steps for regulatory approval.
Jun 2026BusinessLineNews article
Suven Life Sciences finishes enrolling 100 patients for its Phase-2b clinical trial of **ropanicant**, a drug candidate for major depressive disorder (MDD), in the US. The trial completes enrollment ahead of schedule, with preliminary safety data indicating no adverse concerns to date. The company now advances toward evaluating the drug’s efficacy in treating MDD.
Dec 2025BusinessLineNews article